Department of Anesthesia, Crtitical Care and Pain Management, Hôtel Dieu de France hospital, Saint Joseph university school of medicine, P.O.Box 11-5076, Beirut, 1107 2180, Lebanon.
Hôtel Dieu de France Hospital, Alfred NACCACHE Blvd, Ashrafieh, P.O.Box 166830, Beirut, Lebanon.
Obes Surg. 2019 Mar;29(3):911-916. doi: 10.1007/s11695-018-3608-y.
Non-steroidal anti-inflammatory drugs (NSAIDs) are cornerstone in multimodal analgesia protocols. This point is of great value in morbidly obese patients due to the high prevalence of restrictive pulmonary disease and obstructive sleep apnea. The aim of this study was to test the hypothesis that NSAIDs do not increase acute bariatric surgery complications while optimizing postoperative analgesia.
Databases of two medical centers were retrospectively reviewed to find all patients who underwent bariatric surgery between 1 January 2017 and 31 December 2017. Inclusion criteria were BMI greater than 30 kg/m and age of 16-75 years old. Patients who suffered from severe organ failure or coagulation disorders were excluded. Patient's demographics, obesity-related diseases (diabetes, hypertension, dyslipidemia), postoperative pain scores, and morphine consumption in PACU, as well as early and late surgical complications, were collected. Patients included from the first institution (where NSAIDs analgesia was prohibited: control group) were compared to patients from the second institution (where NSAIDs analgesia was mandatory: case group).
The study population included 270 patients, 134 in the control group, and 136 in the case group. NSAIDs usage produced better analgesia with significant reduction in morphine consumption and PACU length of stay. Also, incidence of surgical complications was the same in the two groups.
NSAIDs administration do not increase postoperative complication rate after bariatric surgery. Although NSAID administration provided better analgesia and shorter PACU stay, future prospective studies are needed to confirm these encouraging results and to evaluate their impact on postoperative rehabilitation.
非甾体抗炎药(NSAIDs)是多模式镇痛方案的基石。对于病态肥胖患者,由于限制性肺部疾病和阻塞性睡眠呼吸暂停的高发率,这一点非常重要。本研究的目的是检验 NSAIDs 不会增加肥胖症手术的急性并发症的同时,还能优化术后镇痛的假说。
回顾性地审查了两个医疗中心的数据库,以查找所有在 2017 年 1 月 1 日至 2017 年 12 月 31 日期间接受减肥手术的患者。纳入标准为 BMI 大于 30kg/m2 且年龄在 16-75 岁之间。排除患有严重器官衰竭或凝血障碍的患者。收集患者的人口统计学资料、肥胖相关疾病(糖尿病、高血压、血脂异常)、术后疼痛评分以及 PACU 中的吗啡消耗量,以及早期和晚期手术并发症。将来自第一家机构(禁止使用 NSAIDs 镇痛:对照组)的患者与来自第二家机构(强制使用 NSAIDs 镇痛:病例组)的患者进行比较。
研究人群包括 270 名患者,对照组 134 名,病例组 136 名。使用 NSAIDs 可产生更好的镇痛效果,显著减少吗啡消耗量和 PACU 停留时间。此外,两组的手术并发症发生率相同。
在减肥手术后,使用 NSAIDs 不会增加术后并发症的发生率。尽管 NSAIDs 给药可提供更好的镇痛效果和更短的 PACU 停留时间,但需要进行未来的前瞻性研究来证实这些令人鼓舞的结果,并评估它们对术后康复的影响。